Anumana partners with Novartis for AI-driven heart disease detection
Related Articles
Supporting Predictive Analytics to Improve Clinical Decision Making and Patient Outcomes
As we strive to improve clinical decison making and patient outcomes – predictive analytics are a wonderful tool to help us in that goal. But you can’t just decide to throw predictive analytics into…{post_date: F d, Y}
Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Bioworld: Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ECG-AI detection algorithm is the…{post_date: F d, Y}
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
AI Thority: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of…{post_date: F d, Y}
Mayo Clinic launches two tech companies
Modern Healthcare: One of the companies, Anumana, is seeking clearance from the Food and Drug Administration to market an artificial-intelligence tool to detect heart conditions.{post_date: F d, Y}